IL325116A - New mutants of PD-L2 - Google Patents

New mutants of PD-L2

Info

Publication number
IL325116A
IL325116A IL325116A IL32511625A IL325116A IL 325116 A IL325116 A IL 325116A IL 325116 A IL325116 A IL 325116A IL 32511625 A IL32511625 A IL 32511625A IL 325116 A IL325116 A IL 325116A
Authority
IL
Israel
Prior art keywords
seq
polypeptide
disease
syndrome
amino acid
Prior art date
Application number
IL325116A
Other languages
English (en)
Hebrew (he)
Inventor
Samir N Khleif
Mikayel Mkrtichyan
Isabela Camacho-Horvitz
Original Assignee
Georgiamune Inc
Samir N Khleif
Mikayel Mkrtichyan
Camacho Horvitz Isabela
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgiamune Inc, Samir N Khleif, Mikayel Mkrtichyan, Camacho Horvitz Isabela filed Critical Georgiamune Inc
Publication of IL325116A publication Critical patent/IL325116A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
IL325116A 2023-06-06 2024-06-06 New mutants of PD-L2 IL325116A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363471298P 2023-06-06 2023-06-06
PCT/US2024/032759 WO2024254273A2 (en) 2023-06-06 2024-06-06 Novel pd-l2 mutants

Publications (1)

Publication Number Publication Date
IL325116A true IL325116A (en) 2026-02-01

Family

ID=93794679

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325116A IL325116A (en) 2023-06-06 2024-06-06 New mutants of PD-L2

Country Status (7)

Country Link
EP (1) EP4724474A2 (de)
KR (1) KR20260021697A (de)
CN (1) CN121568956A (de)
AU (1) AU2024284838A1 (de)
IL (1) IL325116A (de)
MX (1) MX2025014536A (de)
WO (1) WO2024254273A2 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110088127A (zh) * 2016-07-28 2019-08-02 高山免疫科学股份有限公司 Cd155变体免疫调节蛋白及其用途
WO2019060888A1 (en) * 2017-09-25 2019-03-28 New York University HETÉRODIMÈRE-FC FUSION PROTEINS
MX2024006897A (es) * 2021-12-10 2024-06-20 Georgiamune Inc Moduladores de polipeptidos.

Also Published As

Publication number Publication date
WO2024254273A3 (en) 2025-02-06
KR20260021697A (ko) 2026-02-13
CN121568956A (zh) 2026-02-24
MX2025014536A (es) 2026-02-03
EP4724474A2 (de) 2026-04-15
WO2024254273A2 (en) 2024-12-12
AU2024284838A1 (en) 2025-12-18

Similar Documents

Publication Publication Date Title
US20240325554A1 (en) Methods for treating cancer
AU2018206015B2 (en) Anti-human 4-1 BB antibodies and use thereof
TWI812918B (zh) IL-7Rαγc結合化合物
EP3494141A1 (de) Identifizierung von vsig3/vista als ein neuartiger immuncheckpoint und verwendung davon zur immuntherapie
WO2015037000A1 (en) Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
TW201412775A (zh) 新穎之ｖｉｓｔａ－ｉｇ構築體及ｖｉｓｔａ－ｉｇ用於治療自體免疫、過敏及發炎病症之用途
US20160304579A1 (en) Polypeptides and uses thereof for treatment of autoimmune disorders and infection
US20250230218A1 (en) Pdl1 peptides for use in cancer vaccines
EP3583113B1 (de) Immunotherapeutische kombination zur behandlung von tgf-alpha-exprimierendem lungenkrebs oder tgf-alpha-exprimierendem melanom
WO2016115218A1 (en) Antibody drug conjugates for the treatment of immune conditions
US20250051419A1 (en) Polypeptide modulators
CA2927817C (en) Novel peptide having 4 linked ctl epitopes
IL325116A (en) New mutants of PD-L2
HK40114371A (zh) 多肽调节物
US20220409711A1 (en) Hla restricted hormad1 t cell receptors and uses thereof
WO2023083439A1 (en) Tlr7 agonist and combinations for cancer treatment
HK40021169A (en) Immunotherapeutic combinaton for the treatment of tgf alpha-expressing lung cancer or tgf alpha expressing melanoma
HK40021169B (en) Immunotherapeutic combinaton for the treatment of tgf alpha-expressing lung cancer or tgf alpha expressing melanoma
HK1224680A1 (en) Novel four-ctl epitope-joined peptide